Skip to content

Enhancing Heart Allograft Function With the OCS Heart System Trial

Enhancing Heart Allograft Function With the OCS Heart System (ENHANCE) Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07145515
Acronym
ENHANCE
Enrollment
655
Registered
2025-08-28
Start date
2026-01-31
Completion date
2027-07-30
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Transplant

Brief summary

This trial is designed to evaluate the safety and effectiveness of the novel OCS Solution and OCS Functional Enhancer (OFE) to support FDA approval in both DBD and DCD heart transplantation. In addition, this trial will evaluate the performance of the novel OCS Solution and OFE compared to Static Cold Storage (SCS) in DBD heart transplantation to potentially demonstrate superiority.

Interventions

DEVICEOCS Heart

Preservation of donor hearts with OCS Heart System and novel OCS Solution and OCS Functional Enhancer.

Preservation of donor hearts with static cold storage.

Sponsors

TransMedics
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Part A - DCD Donor Hearts & DBD Donor Hearts Initially Deemed Unsuitable for Cold Storage (Current Approved Indications): Donor Inclusion Criteria * Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room. * All DCD donors eligible for functional warm ischemic time criteria ≤ 30 minutes. WIT defined as time from when mean systolic blood pressure (SBP) is \<50mmHg (sustained for at least 5 minutes) to aortic cross clamp and administration of old cardioplegia in the donor. * DBD donor hearts with an expected cross clamp of ≥ 4 hours * DBD donor hearts with any of the following organ quality concerns, regardless of cross clamp time: * Donor age ≥ 40 years old * Unknown downtime * Insignificant CAD * LVEF ≤ 50% Donor Exclusion • Moderate to severe aortic incompetence Part B - DBD Donor Hearts Currently Used with Cold Storage (New Indication): Donor Inclusion Criteria * Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room. * Eligible for randomization to OCS or SCS treatment arms. * DBD donor hearts with an expected cross clamp time of \< 4 hours. Donor Exclusion * Moderate to severe aortic incompetence * DBD donor with any of the following organ quality concerns: * Donor age ≥ 40 years old * Unknown downtime * Insignificant CAD * LVEF ≤ 50% Recipient Eligibility Criteria (for Part A and B Cohorts) Inclusion * Signed informed consent document and authorization to use and disclose protected health information * Heart transplant candidate * Age ≥ 18 years old Exclusion • Participant in any other interventional clinical or investigational trials/programs that may confound the outcomes of this trial

Design outcomes

Primary

MeasureTime frameDescription
Patient and graft survival30-day post transplantThe primary endpoint is 30-day patient and graft survival with freedom from moderate or severe LV or RV primary graft dysfunction (PGD) in the first 24 hours post-transplant.

Countries

United States

Contacts

Primary ContactRaicca Haqqi
rhaqqi@transmedics.com978-809-0620
Backup ContactKausar Qidwai
kqidwai@transmedics.com978-494-7105

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026